Meeting
2018 ASCO Annual Meeting
Treatment effect of palbociclib (PAL) plus endocrine therapy (ET) by prognostic and intrinsic subtype: A joint analysis of PALOMA2 and PALOMA3.
Authors
Richard S. Finn
David Geffen School of Medicine at University of California, Los Angeles, Santa Monica, CA
Richard S. Finn , Massimo Cristofanilli , Johannes Ettl , Karen A. Gelmon , Shailendra Verma , Marco Colleoni , Carla Giorgetti , Eric Roland Gauthier , Yuan Liu , Dongrui (Ray) Lu , Cynthia Huang Bartlett , Dennis J. Slamon , Nicholas C. Turner , Hope S. Rugo
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Hormone Receptor-Positive
Clinical Trial Registration Number
NCT01740427, NCT01942135
Citation
J Clin Oncol 36, 2018 (suppl; abstr 1023)
DOI
10.1200/JCO.2018.36.15_suppl.1023
Abstract #
1023
Poster Bd #
104
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Ribociclib (RIB) vs. palbociclib (PAL) in patients (pts) with hormone receptor-positive/HER2-negative/HER2-enriched (HR+/HER2-/HER2-E) advanced breast cancer (ABC): A head-to-head phase III study—HARMONIA SOLTI-2101/AFT-58.
First Author: Tomás Pascual
First Author: Gabrielle Betty Rocque
Poster
2017 ASCO Annual Meeting
Predictors of prolonged benefit from palbociclib (PAL) plus fulvestrant (F) in women with endocrine-resistant hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2–) advanced breast cancer (ABC) in PALOMA-3.
First Author: Massimo Cristofanilli
Poster
2019 ASCO Annual Meeting
Real-world evidence of male breast cancer (BC) patients treated with palbociclib (PAL) in combination with endocrine therapy (ET).
First Author: Cynthia Huang Bartlett